Insomnia symptoms influence CPAP compliance

Purpose

The aim of this study is to determine parameters which influence 6-month compliance of continuous positive airway pressure therapy (CPAP) in patients with obstructive sleep apnea syndrome (OSAS).

Methods

This prospective study investigated 73 patients (24 females) with OSAS and medical indication for CPAP therapy: age 55.1?±?11.5 years, body mass index (BMI) 30.8?±?5.0 kg/m2, Apnea–Hypopnea Index (AHI) 39.2?±?26.7/h, Oxygen Desaturation Index (ODI) 33.2?±?25.4/h, minimum O₂ saturation 78.9?±?7.6%. The influence of baseline parameters (demographic and polysomnographic data, sleeping medication intakes, BMI, psychometrics [Epworth Sleepiness Scale, Regensburg Insomnia Scale, Vigilance test and Beck Depression Inventory]) on 6-month compliance was evaluated with a correlation and a linear regression analysis.

Results

The baseline value of the Regensburg Insomnia Scale (RIS) predicts 6-month CPAP compliance (r?=??0.376, R ²?=?0.14, p?<?0.001), although no other baseline parameter correlates. Patients with a compliance of <4 h/night show higher RIS scores, i.e., more insomnia symptoms (17.6?±?8.8) compared to those with ≥4 h/night (12.6?±?6.9; p?<?0.05).

Conclusions

Insomnia symptoms prior to the beginning of CPAP treatment show a negative influence on CPAP compliance. Further studies should clarify, if a treatment of insomnia symptoms leads to a benefit in compliance.     

The effects of continuous positive airway pressure and mandibular advancement therapy on metabolic outcomes of patients with mild obstructive sleep apnea: a randomized controlled study

Background

Moderate and severe obstructive sleep apnea (OSA) have been independently associated with dyslipidemia. The results of metabolic improvement with continuous positive airway pressure (CPAP) have been controversial. Less evidence exists regarding this issue in mild OSA. A current treatment for mild OSA is mandibular advancement device (MAD) therapy, but its effectiveness on the metabolic profile needs to be compared with CPAP. The purpose of this study was to compare MAD vs CPAP vs no treatment on the metabolic profile during 6 and 12 months of follow-up in patients with mild OSA.

Methods

The inclusion criteria were patients with mild OSA, both genders, ages 18 to 65 years, and body mass index (BMI) of < 35 Kg/m². Patients were randomized in 3 groups (CPAP, MAD, and control). The evaluations included physical examination, metabolic profile, and full polysomnography at baseline, 6 months, and 12 months of follow-up.

Results

Seventy-nine patients with mild OSA were randomized in three treatment groups, with mean age (± SD) of 47?±?9 years, 54% men, and AHI 9.5?±?2.9 events/h. MAD and CPAP reduced AHI at 6 and 12 months compared to the control group. MAD adherence was higher than CPAP at 6 and 12 months. Despite lower adherence compared to MAD, CPAP was more effective in reducing total cholesterol over 12 months (baseline 189.3?±?60.2 mg/dl to 173.4?±?74.3 mg/dl) and low-density lipoprotein cholesterol (LDL-c, baseline 112.8?±?54.9 mg/dl to 94.5?±?67.4 mg/dl).

Conclusions

After 1 year of treatment, CPAP was superior to MAD in reducing total cholesterol and LDL-c in patients with mild OSA.

     

Long-term adherence to ambulatory initiated continuous positive airway pressure in non-syndromic OSA children

Purpose

In children, the usual indications for continuous positive airway pressure (CPAP) are residual OSA after adenotonsillectomy and/or persistent OSA due to obesity. Data concerning adherence (hours/night) following ambulatory CPAP initiation are scarce.

Methods

An observational cohort of 78 children was followed over 2 years. All exhibited sleep-disordered breathing (SDB) symptoms, were assessed by polysomnography, and prescribed CPAP. CPAP was initiated at hospital for 10 children.

Results

OSA children, mean age 10.4?±?3.2 years, were mostly males (75.6%), with a mean body mass index of 21.2?±?7.3 kg/m², and mean apnea+hypopnea index of 12.2?±?10.6 events/hour. Seventy-two children were still on CPAP at 3 months, 63 at 6 months, 55 at 1 year, and 34 at 2 years. CPAP was discontinued thanks to rehabilitation programs, dento-facial orthopedics, and/or weight loss. Mean CPAP adherence at 1, 3, 6, 12, and 24 months was respectively 6.1?±?2.8, 6.2?±?2.6, 6.2?±?2.8, 6.3?±?2.8, and 7.0?±?2.7 h/night. There was a trend towards higher CPAP adherence and younger age, primary versus middle/high school attendance, higher baseline apnea+hypopnea index, and neurocognitive disorders.

Conclusion

In our population, mean CPAP adherence defined in hours per night was high and did not decrease during the 24-month follow-up. These findings support the feasibility of ambulatory CPAP initiation in non-syndromic OSA. The high CPAP adherence is expected to be associated with improvements in neurocognition, and in metabolic and cardiovascular parameters.

     

Effect of Continuous Positive Airway Pressure Therapy on Aortic Stiffness in Patients with Obstructive Sleep Apnea Syndrome

Objective: The most significant complications seen in patients with obstructive sleep apnea syndrome (OSAS) are associated with the cardiovascular system. The present study assessed aortic stiffness in patients with OSAS and evaluated the effect of continuous positive airway pressure (CPAP) therapy on aortic stiffness. Method: Twenty‐four patients with newly diagnosed, previously untreated, moderate or severe OSAS (apnea‐hypopnea index > 15) and a control group of 17 healthy patients were included in the study. M‐mode recordings of the ascending aorta were taken from the parasternal long axis by echocardiograhy, and systolic and diastolic diameters of the aorta were measured. Aortic elastic parameters, aortic strain, and distensibility were calculated. Measurements were repeated after 6 months of CPAP therapy in patients with OSAS and were compared with baseline values. Results: In patients with OSAS, compared with the control group, aortic strain (6.7%± 2.1% vs. 12.4%± 3.1%; P < 0.001) and aortic distensibility (2.8 ± 0.9 × 10^?6 cm² dyn^?1 vs. 5.5 ± 1.7 × 10^?6 cm² dyn^?1; P < 0.001) were evidently lower, and there was a significant correlation between aortic elastic parameters and AHI. After a 6‐month course of CPAP therapy, significant increases were observed in aortic strain (6.1%± 1.5% vs. 7.3%± 1.7%; P < 0.001) and aortic distensibility (2.5 ± 0.7 × 10^?6 cm² dyn^?1 vs. 3.1 ± 0.9 × 10^?6 cm² dyn^?1; P < 0.001) in patients with OSAS. Conclusion: Aortic strain and distensibility were lower in patients with OSAS than in control patients, and CPAP treatment provided improvement in aortic elastic parameters. (ECHOCARDIOGRAPHY, Volume 26, November 2009)     

Obstructive sleep apnea and craniofacial appearance in MPS type I-Hurler children after hematopoietic stem cell transplantation

Objectives

Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disorder characterized by severe multi-systemic organ manifestations including obstructive sleep apnea syndrome (OSAS). Hematopoietic stem cell transplantation (HSCT) is the treatment of choice in severe MPS I (MPS IH, Hurler syndrome). However, the effect of HSCT on OSAS in MPS IH still remains unclear. The purpose of this study was to analyze respiratory patterns during sleep following HSCT in MPS IH children and to relate these findings to craniofacial abnormalities.

Methods

Overnight polysomnographies of nine MPS IH children (mean age: 8.2 years) previously treated with HSCT were retrospectively analyzed. Magnetic resonance images of the head were assessed with regard to soft and hard tissue abnormalities of the upper respiratory tract.

Results

The mean apnea hypopnea index (AHI) was 5.3 events/h (range, 0.3–12.2), and the majority of apnea/hypopneas were obstructive. Whereas two patients had severe OSAS (AHI?>?10) and two moderate OSAS (5?>?AHI?<?10), five patients had no evidence of OSAS (AHI?<?2.0). Donor cell chimerism was significantly lower in MPS IH patients with OSAS as compared to patients without OSAS (p?<?0.001). The upper airway space and the maxilla were significantly smaller and the adenoids larger in MPS IH patients with OSAS as compared to those of non-OSAS patients.

Conclusion

OSAS was only observed in MPS IH patients with graft failure or low donor cell chimerism. Conversely, successful HSCT seems to ameliorate adenoid hyperplasia and maxillary constriction in MPS IH patients and thereby minimizes the risk of OSAS at least at younger ages.

     

Pressure adjustment is the most useful intervention for improving compliance in telemonitored patients treated with CPAP in the first 6 months of treatment

Purpose

Telemonitoring (TMg) for patients treated with continuous positive airway pressure (CPAP) is now routine care in some sleep labs. The purpose of the present study was to identify technical interventions associated with improved CPAP compliance in a real-life cohort of newly telemonitored patients with obstructive sleep apnea (OSA) during the first 6 months of treatment.

Methods

All patients with moderate-to-severe OSA (apnea-hypopnea index (AHI) ≥ 15/h) who were newly treated with CPAP were included in the study and telemonitored. A group educational session was scheduled after 1 month. Technical interventions were performed at the patient’s request and during scheduled visits and the impact of each intervention on CPAP therapy compliance was collected.

Results

Between May 2018 and Dec 2019, 349 patients newly diagnosed with OSA were hospitalized in the sleep lab for CPAP titration and 212 patients were included (mean age 54.6 ± 13.1 years, mean BMI 31.7 ± 5.8 kg/m², mean AHI 42.8 ± 22.0). TMg acceptance rate was 87%. Mean 6-month compliance was 275 ± 154 min, 13% stopped CPAP, and 17% were non-compliant. Correlations were observed between BMI (r = 0.15, p = 0.029), median and 95th percentile leaks (r = ?0.23 and ?0.18, p = 0.016 and 0.002), and CPAP compliance.

During follow-up, 92 interventions were required, mainly for mask change (n = 80). Pressure modification (n = 16) was the only intervention that increased CPAP use > 30 min/night, p = 0.021.

Conclusion

Pressure modification was the only adaptation that significantly increased CPAP compliance during the first 6 months. Remote TMg allows providing daily, accurate, and immediate feedback that could help clinicians to confirm that the CPAP treatment is effective.

     

Continuous positive airway pressure intolerance associated with elevated nasal resistance is possible mechanism of complex sleep apnea syndrome

Purpose

Complex sleep apnea syndrome (CompSAS) is diagnosed after an elimination of obstructive events with continuous positive airway pressure (CPAP), when a central apnea index ??5/h or Cheyne?CStokes respiration pattern emerges in patients with obstructive sleep apnea syndrome (OSAS). However, the pathophysiology of CompSAS remains controversial.

Methods

Of the 281 patients with suspected OSAS, all of whom underwent polysomnography conducted at Nagoya University Hospital, we enrolled 52 patients with apnea?Chypopnea index ??15/h (age 51.4?±?13.3?years). The polysomnographic findings, left ventricular ejection fraction (LVEF), and nasal resistance were compared between the CompSAS patients and OSAS patients.

Results

Forty-three patients were diagnosed with OSAS and nine patients with central sleep apnea syndrome by natural sleep PSG. Furthermore, 43 OSAS patients were classified into the OSAS patients (OSAS group, n?=?38) and the CompSAS patients (CompSAS group, n?=?5) by the night on CPAP PSG. The nasal resistance was significantly higher in CompSAS group than in OSAS group (0.30?±?0.10 vs. 0.19?±?0.07?Pa/cm³/s, P?=?0.004). The arousal index, percentage of stage 1 sleep, and oxygen desaturation index were significantly decreased, and the percentage of stage REM sleep was significantly increased in the OSAS group with the initial CPAP treatment, but not in the CompSAS group. In addition, the patients with CompSAS showed normal LVEF.

Conclusion

CPAP intolerance secondary to an elevated nasal resistance might relate to frequent arousals, which could presumably contribute to an increase in central sleep apnea. Further evaluation in a large study is needed to clarify the mechanism of CompSAS.     

Auto bi-level pressure relief–PAP is as effective as CPAP in OSA patients—a pilot study

Purpose

Continuous positive airway pressure (CPAP) is the therapy of choice for the treatment of obstructive sleep apnea (OSA). Not all patients can use CPAP therapy with adequate compliance. There is a need to develop more comfortable modes. Auto bi-level Pressure Relief-Positive Airway Pressure (ABPR-PAP) can be an alternative. We conducted a prospective double-blind, randomised trial to evaluate the efficacy and compliance of ABPR-PAP compared with CPAP in OSA patients.

Methods

We included 35 CPAP naive patients (age 53.3?±?10.3?years, BMI 31.0?±?5.0?kg/m², ESS 10.0?±?4.2) diagnosed with moderate to severe OSA who underwent a successful CPAP titration. Patients were randomised into the CPAP or the ABPR-PAP treatment group. We used the same device (BIPAP? Auto, Philips Respironics) for CPAP or ABPR-PAP. Apnea?Chypopnea index (AHI) was determined using polysomnography before (AHI 40.6?±?18.3 per hour) and after treatment.

Results

Eighteen patients received CPAP and the remaining 17 received APBR-PAP. Groups were similar in terms of demographics and OSA severity. There were no serious adverse events during the trial. CPAP was fixed by a sleep expert and ABPR-PAP varied (range 5?C15?cmH₂O). AHI decreased in the CPAP group to 6.4?±?5.7 per hour and in the ABPR-PAP group to 4.8?±?3.6 per hour in the first night (N?=?35). After 3?months, the AHI decreased in the CPAP group to 4.4?±?5.3 per hour and in the ABPR-PAP group to 2.6?±?3.8 per hour (N?=?32). Differences between the groups were not statistically significant. There were no differences in compliance.

Conclusions

ABPR-PAP is a promising new ventilation mode that enables effective treatment of OSA patients.     

Serum vitamin D levels in patients with obstructive sleep apnea syndrome and level changes after continuous positive airway pressure therapy

Purpose

Patients with obstructive sleep apnea syndrome (OSAS) have been found to exhibit lower serum vitamin D levels, even when the control groups are matched for confounding conditions. However, contradictory studies are also present. This study aimed to compare serum 25-hydroxyvitamin D (25(OH)D) levels between adult patients with OSAS and non-apneic controls and to evaluate the changes in 25(OH)D levels after 3 and 12 months of continuous positive airway pressure (CPAP) therapy.

Methods

The study was comprised of 30 patients with OSAS and 30 controls. Serum 25(OH)D levels were determined at baseline and after 3 and 12 months of CPAP therapy in all patients with OSAS. For analysis, patients with OSAS were divided into subgroups by adherence, with adherence defined as CPAP usage for > 4 h per night on at least 70% of nights.

Results

The 25(OH)D levels were not significantly different between OSAS and control groups at baseline. 25(OH)D levels did not change after 3 and 12 months of CPAP therapy. Patients who were CPAP-adherent showed less reduction in 25(OH)D levels compared with non-adherent ones (21.18 ± 9.3 vs. 12.13 ± 3.8 ng/mL, p = 0.022) after 1 year. The 25(OH)D levels were significantly correlated with higher daily CPAP usage at 3 and 12 months. Mean daily CPAP usage was a significant predictor of serum 25(OH)D levels at 12 months.

Conclusions

Patients with OSAS who demonstrated good CPAP adherence showed significantly higher 25(OH)D levels after 1 year compared with those not adequately using CPAP. Long-term good CPAP adherence and highly daily CPAP usage positively affected 25(OH)D levels in patients with OSAS.

     

Lack of association between obstructive sleep apnea syndrome and specular microscopic features of the corneal endothelium

Background

Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of hypoxemia and hypercapnia during sleep. The aim of this study was to determine whether OSAS causes significant changes in corneal endothelium detectable by specular microscopy.

Methods

This prospective, cross-sectional study compared the specular microscopic features of the corneal endothelium of patients with OSAS and age-and gender-matched controls. Patients diagnosed with OSAS by polysomnography in the sleep unit were classified using apnea-hypopnea indexes into two groups as mild-moderate OSAS group and severe OSAS group. All participants were divided into three age groups: 30–45, 46–60, and >?60 years. Corneal endothelial cell density (ECD), percentage of hexagonal cells (Hex), and coefficient of variation of cell area (CV) were obtained using a non-contact specular microscope. The measurements of each group were compared statistically.

Results

A total of 66 patients (51.1?±?9.4 years) and 88 controls (49.2?±?10.5 years) were examined. The mild-moderate OSAS group and the severe OSAS group had no significant differences in measures of specular microscopy compared with the controls (ECD, p?=?0.84; Hex, p?= 0.18; CV, p?=?0.41). The mean values of ECD, Hex, and CV were 2552.56?±?302.49 cells/mm², 54.13?±?8.13%, and 36.41?±?5.92, respectively, in the mild-moderate OSAS group; 2510.52?±?377.12 cells/mm², 54.85?±?8.68%, and 34.77?±?5.02, respectively, in the severe OSAS group; 2543.37?±?286.94 cells/mm², 51.89?±?9.09%, and 36.03?±?5.32, respectively, in the control group.

Conclusions

There were no significant differences in corneal endothelial features between patients and controls. Although OSAS causes systemic hypoxia, its effects do not appear to result in corneal endothelial alterations detectable by specular microscopy.

     

Continuous Positive Airway Pressure Adherence In Patients with Obstructive Sleep Apnea &amp; Symptomatic BPH

Purpose To determine the short-term and long-term adherence rates with continuous positive airway pressure (CPAP) therapy in sleep apnea patients with benign prostatic hyperplasia (BPH) compared to matched controls. Methods A case–control retrospective analysis was performed in a veterans affairs hospital. All symptomatic patients with BPH (n?=?107) ever started on CPAP therapy between 2006 and 2012 were compared with controls matched for severity of sleep apnea (AHI). Adherence measures were obtained at the third and twelfth month visits. The cases included symptomatic BPH patients on active medical therapy. Diuretic use among cases and controls, and severity of nocturia among the cases were also analyzed. Results The mean AHI among cases and controls was 35.6?±?27.3 and 35.5?±?31 (p?=?0.96). The population was male and predominantly Caucasian. There was no statistically significant difference in percent days CPAP device use ≥4 h. between symptomatic BPH patients and controls at 3-month (51.6?±?38 vs. 47.2?±?36; p?=?0.43) and 1-year (64?±?40.5 vs. 64.7?±?31.3; p?=?0.90) visits. The use of diuretics in the cases and controls, and the severity of nocturia in the cases did not influence adherence with CPAP therapy. Conclusions BPH or diuretic use did not affect adherence with CPAP therapy in obstructive sleep apnea. Severity of nocturia did not have any influence on adherence among the cases. BPH, regardless of the severity of nocturia, and diuretic use does not influence CPAP adherence in patients with OSA.     

Gender-specific change in leptin concentrations during long-term CPAP therapy

Purpose

Nasal continuous positive airway pressure (CPAP) alleviates sleepiness in patients with obstructive sleep apnoea syndrome (OSAS), but part of OSAS patients keep gaining weight. Leptin and insulin-like growth factor-1 (IGF-1) interact with energy balance, and CPAP therapy has been suggested to influence these endocrine factors. We hypothesised that leptin would decrease during long-term CPAP therapy, and weight gain would associate with OSAS severity, lower CPAP adherence, lower IGF-1, and leptin concentrations.

Methods

Consecutive patients (n?=?223) referred to sleep study with suspected OSAS were enrolled. Patients underwent cardiorespiratory polygraphy at baseline. Questionnaires were completed, and blood samples were drawn both at baseline and after 3 years. A total of 149 (67%; M 65, F 84) patients completed the follow-up. Plasma samples were available from 114 patients, 109 of which with CPAP adherence data (49 CPAP users, 60 non-users).

Results

At baseline, the CPAP users were more obese and had more severe OSAS than the non-users. Leptin concentrations did not differ. After follow-up, leptin concentrations were higher in CPAP users (30.2 ng/ml vs. 16.8 ng/ml; p?=?0.001). In regression analysis, increase in leptin concentrations was independent of age, baseline body mass index (BMI), or the change in BMI. Leptin concentrations increased among females (??8.9 vs. 12.7 ng/ml; p?<?0.001); whereas in men, CPAP did not have an effect, if not opposed the natural decrease in leptin observed in men not using CPAP. Change in IGF-1 levels did not differ.

Conclusions

Our results suggest increase in leptin concentrations during long-term CPAP therapy among females.

     

The effects of continuous positive airway pressure therapy on mean platelet volume in patients with obstructive sleep apnea

Previous studies have reported increased platelet activation and aggregation in patients with obstructive sleep apnea (OSA). Continuous positive airway pressure (CPAP) treatment has been shown to decrease platelet activation. We aimed to study the effects of nasal CPAP therapy has on MPV values in patients with severe OSA. Thirty-one patients (21 men; mean age 53.8?±?9.2 years) with severe OSA (AHI?>?30 events/hour) constituted the study group. An age, gender and body mass index (BMI) matched control group was composed 25 subjects (14 men; mean age 49.6?±?8.5 years) without OSA (AHI?<?5 events/hour). We measured MPV values in patients with severe OSA and control subjects and we measured MPV values after 6 months of CPAP therapy in severe OS patients. The median (IQR) MPV values were significantly higher in patients with severe OSA than in control group (8.5 [8.3–9.1] vs. 8.3 [7.5–8.8] fL; p?=?0.03). The platelet counts were significantly lower in patients with severe OSA than in control group (217.8?±?45.9 vs. 265.4?±?64.0?×?10⁹/L; p?=?0.002). The six months of CPAP therapy caused significant reductions in median (IQR) MPV values in patients with severe OSA (8.5 [8.3–9.1] to 7.9 [7.4–8.2] fL; p?<?0.001). Six months of CPAP therapy caused significant increase in platelet counts when compared with baseline values (217.8?±?45.9 to 233.7?±?60.6?×?10⁹/L; p?<?0.001). We have found that the MPV values of patients with severe OSA were significantly higher than those of the control subjects and 6 months CPAP therapy caused significant reductions in the MPV values in patients with severe OSA.     

Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea with Schizophrenia

Introduction

To determine the 1-year and 3-year adherence rates with Positive Airway Pressure (PAP) therapy in patients with schizophrenia compared to matched controls.

Methods

A case–control retrospective analysis was performed in a Veterans Affairs hospital. All symptomatic patients with schizophrenia ever started on PAP therapy between 2007 and 2015 were compared with controls matched for severity of sleep apnea based on AHI, BMI, and age at the time of diagnosis.

Results

Total number of subjects in both groups was 39. Mean AHI among cases and controls was 27.63 ± 22.16 and 33.59 ± 44.04 (p = 0.32), mean BMI was 34.91 ± 5.87 and 33.92 ± 5.21 (p = 0.43), and mean age at diagnosis was 53.6 ± 11.75 and 55.97 ± 11.92 (p = 0.36), respectively. There was no statistically significant difference in PAP use between patients with schizophrenia and controls at 1-year (percent days device use > 4 h—36.43% ± 31.41 vs. 49.09% ± 38.76; p = 0.17) and 3-year (percent days device use > 4 h—42.43 ± 35.50 vs. 60.53 ± 38.56; p = 0.089) visits

Conclusions

PAP adherence and usage is not significantly different among patients with schizophrenia compared to matched controls. Therefore, schizophrenia does not appear to influence CPAP compliance.

     

Impact of mandibular advancement device therapy on cerebrovascular reactivity in patients with carotid atherosclerosis combined with OSAHS

Purpose

Obstructive sleep apnea-hypopnea syndrome (OSAHS) may affect cerebrovascular reactivity (CVR), representing cerebrovascular endothelial function, through complex cerebral functional changes. This study aimed to evaluate the change of CVR after 1-month and 6-month mandibular advancement device (MAD) treatment of patients with carotid atherosclerosis (CAS) combined with OSAHS.

Methods

Patients with carotid atherosclerosis combined with OSAHS who voluntarily accepted Silensor-IL MAD therapy were prospectively enrolled. All patients underwent polysomnographic (PSG) examinations and CVR evaluation by breath-holding test using transcranial Doppler ultrasound at baseline (T0), 1 month (T1), and 6 months (T2) of MAD treatment.

Results

Of 46 patients (mean age 54.4 ± 12.4 years, mean body mass index [BMI] 27.5 ± 4.5 kg/m²), 41 patients (responsive group) responded to the 1-month and 6-month treatment of MAD, an effective treatment rate of 89%. The remaining 5 patients (non-responsive group) were younger (47.4?±?13.5 years) and had a higher BMI (35.8?±?1.8 kg/m²). The responsive group had an improvement of apnea-hypopnea index (AHI) (events/h) from 33.0?±?25.0 (T0) to 12.4?±?10.4 (T1) and 8.7?±?8.8 (T2), P?<?0.001; minimum arterial oxygen saturation (minSpO₂) (%) increased from 79.8?±?9.1 (T0) to 81.8?±?9.4 (T1) and 85.2?±?5.4 (T2), P?<?0.01; longest apnea (LA) (s) decreased from 46.5?±?23.1 (T0) to 33.3?±?22.7 (T1) and 29.4?±?18.5 (T2), P?<?0.001; T90 (%) decreased from 10.3?±?14.9 (T0) to 6.1?±?11.8 (T1) and 3.3?±?7.5 (T2), P?<?0.05. Sleep architecture of these patients also improved significantly. The responsive group had a significant increase in left, right, and mean breath-holding index (BHI): left BHI(/s) from 0.52?±?0.42 (T0) to 0.94?±?0.56 (T1) and 1.04?±?0.64 (T2), P?<?0.01; right BHI(/s) from 0.60?±?0.38 (T0) to 1.01?±?0.58 (T1) and 1.11?±?0.60 (T2), P?<?0.01; mean BHI(/s) from 0.56?±?0.38 (T0) to 0.97?±?0.55 (T1) and 1.07?±?0.59 (T2), P?<?0.01), suggesting improved CVR.

Conclusion

Effective MAD therapy is beneficial for restoring cerebrovascular endothelial function in patients with CAS and OSAHS in a short period (1 month and 6 months).

Trial registration

Clinical trial registration number: NCT03665818. September 11, 2018.

     

Association between continuous positive airway pressure and circulating omentin levels in patients with obstructive sleep apnoea

Purpose

Inflammation and oxidative stress play important roles in the pathogenesis of obstructive sleep apnoea syndrome (OSAS). Omentin is expressed in visceral adipose tissue and is associated with the inflammatory response. The aim of this study was to assess the relationship between OSAS and omentin based on a comparison of its serum levels at baseline and after 3 months of continuous positive airway pressure (CPAP) therapy.

Methods

Ninety-six newly diagnosed OSAS patients and 31 non-apnoeic controls were enrolled in this study. Blood samples were obtained in the morning after polysomnography. Within the OSAS group, 30 patients were started on CPAP therapy and then reassessed clinically, including a blood test for serum omentin and other biochemical analysis, at 3 months.

Results

Serum omentin levels were significantly lower in the OSAS group than in the control group (27.7?±?7.6 and 42.5?±?5.2 ng/mL, P?<?0.001). In the subgroup analysis, omentin concentrations were significantly lower in patients with severe OSAS than in those with mild/moderate OSAS (P?<?0.001). Circulating omentin levels were significantly correlated with the apnoea–hypopnoea index (AHI), mean SaO₂, oxygen desaturation index, and serum C-reactive protein levels. Treatment with CPAP resulted in a significant increase in circulating omentin levels after 3 months, from 22.7?±?1.4 to 41.2?±?3.3 ng/mL (P?<?0.001).

Conclusions

OSAS is associated with low serum omentin levels, and these levels can be reversed by effective CPAP treatment.

     

Cerebral hemodynamic changes in obstructive sleep apnea syndrome after continuous positive airway pressure treatment

Background

Patients with obstructive sleep apnea syndrome (OSAS) are at increased risk for cerebrovascular diseases. The underlying mechanisms remain obscure. It may occur through a reduction in cerebral vascular reactivity. Continuous positive airway pressure (CPAP) is effective in reducing the occurrence of apneas. We hypothesized that treatment with CPAP improves cerebral vascular reactivity.

Methods

This is a prospective study with OSAS patients. The apnea test (ApT) was calculated as an increase of mean artery velocity during apnea: [Artery velocity in apnea minus Resting artery velocity]/Resting artery velocity expressed as percentage. After 2 years of CPAP treatment, the test was repeated.

Results

Seventy-six patients represented the study pool. After 2 years of treatment with CPAP, we were able to conduct a reassessment in 65 patients. Of the 65 patients who finished the clinical study, 56 were men, and 9 were women, with an average age of 48.1?±?10.4 years. There was an improvement in the ApT after CPAP treatment (30.8?±?12.1 vs 39.8?±?15.1; p:0.000). The values of cerebral blood flow velocities, diastolic blood pressure in apnea, and basal heart rate decreased.

Conclusions

Cerebral vascular reactivity in OSAS patients measured by ApT improved after 2 years of CPAP.     

Treatment of obstructive sleep apnea using a custom-made titratable duobloc oral appliance: a prospective clinical study

Purpose

This prospective clinical study investigates the efficacy of a specific custom-made titratable mandibular advancement device (MAD) for the treatment of obstructive sleep apnea (OSA). This MAD has attachments in the frontal teeth area that allow for progressive titration of the mandible.

Methods

Sixty-one adult OSA patients were included (age, 46.7?±?9.0 years; male/female ratio, 45/16; apnea–hypopnea index (AHI), 23.2?±?15.4 events/h sleep; body mass index, 27.9?±?4.1 kg/m²). After an adaptation period, titration started based on a protocol of symptomatic benefit or upon reaching the physiological limits of protrusion. As a primary outcome, treatment response was defined as an objective reduction in AHI following MAD treatment of ≥50 % compared to baseline, and treatment success as a reduction in AHI with MAD to less than 5 and 10 events/h sleep. Compliance failure was defined as an inability to continue treatment.

Results

A statistically significant decrease was observed in AHI, from 23.4?±?15.7 at baseline to 8.9?±?8.6 events/h with MAD (p?<?0.01). Treatment response was achieved in 42 out of 61 patients (68.8 %), whereas 42.6 % met criteria of AHI?<?5 and 63.9 % achieved an AHI?<?10 events/h sleep, respectively. Four patients (6.6 %) were considered as “compliance failures.”

Conclusions

The present study has evaluated the efficacy of a specific custom-made titratable MAD in terms of sleep apnea reduction.     

Determination of new prediction formula for nasal continuous positive airway pressure in Turkish patients with obstructive sleep apnea syndrome

Background

Race/ethnicity may play an important role in determining body size, severity of obstructive sleep apnea syndrome (OSAS), and effective continuous positive airway pressure (CPAP) (Peff). Turkey is composed of different ethnic groups. Therefore, the aims of this study were to determine new prediction formula for CPAP (Ppred) in Turkish OSAS patients, validate performance of this formula, and compare with Caucasian and Asian formulas.

Methods

Peff of 250 newly diagnosed moderate-to-severe OSAS patients were calculated by in-laboratory manual titration. Correlation and multiple linear regression analysis were used to model effects of ten anthropometric and polysomnographic variables such as neck circumference (NC) and oxygen desaturation index (ODI) on Peff. New formula was validated in different 130 OSAS patients and compared with previous formulas.

Results

The final prediction formula was $ {\text{Ppred}} = \left( {0.{148} \times {\text{NC}}} \right) + \left( {0.0{38} \times {\text{ODI}}} \right) $ . When Peff of control group was assessed, it was observed that mean Peff was 8.39?±?2.00?cmH₂O and Ppred was 8.23?±?1.22?cmH₂O. Ppred was within ±3?cmH₂O of Peff in 96.2% patients. Besides, Peff was significantly correlated with new formula, and prediction formulas developed for Caucasian and Asian populations (r?=?0.651, p?<?0.001, r?=?0.648, p?<?0.001, and r?=?0.622, p?<?0.001, respectively).

Conclusions

It is shown that level of CPAP can be successfully predicted from our prediction formula, using NC and ODI and validated in Turkish OSAS patients. New equation correlates with other formulas developed for Caucasian and Asian populations. Our simple formula including ODI, marker of intermittent hypoxia, may be used easily in different populations.     

Nasal versus oronasal continuous positive airway pressure masks for obstructive sleep apnea: a pilot investigation of pressure requirement, residual disease, and leak

Purpose

This single-blinded, randomized, controlled pilot study aimed to investigate whether there is a difference between nasal and oronasal masks in therapeutic continuous positive airway pressure (CPAP) requirement, residual disease, or leak when treating obstructive sleep apnea (OSA) and if differences were related to measures of upper airway size.

Methods

Patients with severe OSA currently using CPAP at ??4?h/night with a nasal mask were examined (including Mallampati scale, incisal relationship, and mandibular protrusion) and then randomized to receive auto-positive airway pressure (PAP) or fixed CPAP at a manually titrated pressure for 1?week each at home, with immediate crossover. Within each week, a nasal mask and two oronasal masks were to be used for two or three nights each in random order. Data were downloaded from the device.

Results

Twelve patients completed the trial (mean ± SD AHI 59.8?±?28.6 events/h; CPAP 11.1?±?3.2?cmH₂O; BMI 37.7?±?5.0?kg/m²). During auto-PAP, the median 95th percentile pressure delivered with all masks was within 0.5?cmH₂O (p?>?0.05). During CPAP, median residual AHI was 0.61 (IQR?=?1.18) for the nasal mask, 1.70 (IQR?=?4.04) for oronasal mask 1, and 2.48 (IQR?=?3.74) for oronasal mask 2 (p?=?0.03). The 95th percentile leak was lowest with the nasal mask during both CPAP and auto-PAP (both p?Conclusions In obese OSA patients changing from a nasal to oronasal mask increased leak and residual AHI but did not affect the therapeutic pressure requirement. The findings of the current study highlight mask leak as the major difficulty in the use of oronasal masks.